Table 2.
Correlation of MAP3K3 Expression with Clinicopathological Parameters in HGSOC Patients.
| Characteristics | N (105) | MAP3K3 expression | |||
|---|---|---|---|---|---|
| Overexpression | Low expression | χ2 | P | ||
| Age | |||||
| > 50 | 65 | 47 (72.3) | 18 (27.7) | 0.275 | 0.600 |
| ≤50 | 40 | 27 (67.5) | 13 (32.5) | ||
| FIGO stage | |||||
| I + II | 33 | 16 (48.5) | 17 (51.5) | 9.063 | 0.003** |
| III + IV | 39 | 32 (82.1) | 7 (17.9) | ||
| Unknown | 33 | ||||
| Ascites | |||||
| Yes | 45 | 31 (68.9) | 14 (31.1) | 0.835 | 0.361 |
| No | 16 | 9 (56.2) | 7 (43.8) | ||
| Unknown | 44 | ||||
| Chemotherapy response | |||||
| Sensitive | 39 | 20 (51.3) | 19 (48.7) | 3.892 | 0.049* |
| Partially sensitive | 12 | 10 (83.3) | 2 (16.7) | ||
| Unknown response | 54 | ||||
Abbreviations: HGSOC, High-Grade serous ovarian carcinoma.